| abstract |
Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists of IL-21 or IL-21 receptor ('IL-21R' or 'MU-1'), are disclosed. IL-21/IL-21R agonists can be used by themselves or in combination with 5 anti-inflammatory agents to treat, e.g., ameliorate, symptoms associated with immunological disorders of the nervous system, e.g., multiple sclerosis. |